Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 16/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | HTR1A | P08908 | 1/20 | 0.61 |
| ▸ | DRD2 | P14416 | 1/20 | 0.61 |
| ▸ | DRD1 | P21728 | 1/20 | 0.61 |
| ▸ | DRD5 | P21918 | 1/20 | 0.61 |
| ▸ | HTR2A | P28223 | 1/20 | 0.61 |
| ▸ | DRD3 | P35462 | 1/20 | 0.61 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.59 |
| ▸ | MAOB | P27338 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4670302 | 0.94 | HRH3 (0.72) | HRH3KCNH2CYP3A4CYP2C9DRD2 | |
| Hydrochloric Acid SCHEMBL5935439 | 0.88 | HRH3 (0.65) | HRH3KCNH2CYP3A4CYP2C9MAOB | |
| SCHEMBL4670300 | 0.88 | HRH3 (0.65) | HRH3KCNH2CYP3A4CYP2C9DRD3 | |
| SCHEMBL4670297 | 0.88 | HRH3 (0.62) | HRH3KCNH2CYP3A4CYP2C9MAOB | |
| SCHEMBL4672399 | 0.86 | HRH3 (0.65) | HRH3KCNH2CYP3A4CYP2C9DRD2 | |
| SCHEMBL4674376 | 0.83 | HRH3 (0.73) | HRH3KCNH2CYP3A4CYP2C9MAOB | |
| SCHEMBL4670679 | 0.83 | HRH3 (0.73) | HRH3KCNH2CYP3A4CYP2C9MAOB | |
| SCHEMBL4670890 | 0.82 | HRH2 (0.59) | HRH3KCNH2CYP3A4CYP2C9MAOB | |
| Hydrochloric Acid SCHEMBL5935356 | 0.82 | HRH3 (0.87) | HRH3KCNH2DRD2MAOB | |
| SCHEMBL4089542 | 0.80 | HRH3 (0.97) | HRH3KCNH2DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1610786-B9 | 4-(4-(HETEROCYCLYLALKOXY PHENYL)-1-(HETEROCYCLYL-CARBONYL)PIPERIDINE DERIVATIVES AND RELATED COMPOUNDS AS HISTAMINE H3 ANTAGONISTS FOR THE TREATMENT OF NEUROLOGICAL DISEASES SUCH AS ALZHEIMER'S | GLAXO GROUP LTD (GB) | 2008-02-27 | — | — | EP | claimed |
| EP-1610786-B1 | 4-(4-(HETEROCYCLYLALKOXY PHENYL)-1-(HETEROCYCLYL-CARBONYL)PIPERIDINE DERIVATIVES AND RELATED COMPOUNDS AS HISTAMINE H3 ANTAGONISTS FOR THE TREATMENT OF NEUROLOGICAL DISEASES SUCH AS ALZHEIMER'S | GLAXO GROUP LTD (GB) | 2007-06-20 | — | — | EP | claimed |
| US-20060205774-A1 | 4-(4-(Heterocyclylakoxy) phenyl-1-(heterocyclyl-carbonyl) piperidine derivavites and related compounds as histamine h3 antagonists for the treatment of neurological diseases such as alzheimer's | GLAXO GROUP LIMITED (GB) | 2006-09-14 | — | — | US | claimed |
| EP-1610786-A1 | 4-(4-(HETEROCYCLYLALKOXY PHENYL)-1-(HETEROCYCLYL-CARBONYL)PIPERIDINE DERIVATIVES AND RELATED COMPOUNDS AS HISTAMINE H3 ANTAGONISTS FOR THE TREATMENT OF NEUROLOGICAL DISEASES SUCH AS ALZHEIMER'S | GLAXO GROUP LIMITED (GB) | 2006-01-04 | — | — | EP | claimed |
| WO-2004089373-A1 | 4- (4-(HETEROCYCLYLALKOXY}PHENYL)-1-(HETEROCYCLYL-CARBONYL)PIPERIDINE DERIVATIVES AND RELATED COMPOUNDS AS HISTAMINE H3 ANTAGONISTS FOR THE TREATMENT OF NEUROLOGICAL DISEASES SUCH AS ALZHEIMER’S | GLAXO GROUP LIMITED (GB) | 2004-10-21 | — | — | WO | claimed |
| EP-1610786-B9 | 4-(4-(HETEROCYCLYLALKOXY PHENYL)-1-(HETEROCYCLYL-CARBONYL)PIPERIDINE DERIVATIVES AND RELATED COMPOUNDS AS HISTAMINE H3 ANTAGONISTS FOR THE TREATMENT OF NEUROLOGICAL DISEASES SUCH AS ALZHEIMER'S | GLAXO GROUP LTD (GB) | 2008-02-27 | — | — | EP | disclosed |
| EP-1610786-B1 | 4-(4-(HETEROCYCLYLALKOXY PHENYL)-1-(HETEROCYCLYL-CARBONYL)PIPERIDINE DERIVATIVES AND RELATED COMPOUNDS AS HISTAMINE H3 ANTAGONISTS FOR THE TREATMENT OF NEUROLOGICAL DISEASES SUCH AS ALZHEIMER'S | GLAXO GROUP LTD (GB) | 2007-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205774-A1 | 4-(4-(Heterocyclylakoxy) phenyl-1-(heterocyclyl-carbonyl) piperidine derivavites and related compounds as histamine h3 antagonists for the treatment of neurological diseases such as alzheimer's | HRH3, HRH4, HRH1 | HRH3 1/4885KCNH2 311/4885CYP3A4 894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.